- Visibility 376 Views
- Downloads 337 Downloads
- Permissions
- DOI 10.18231/j.jdpo.2025.017
-
CrossMark
Dedifferentiated liposarcoma - A case report
- Author Details:
-
Kunjan Patel
-
Isha Pathak *
-
Minesh Gandhi
-
Deep Chauhan
Kunjan Patel
Isha Pathak *
Minesh Gandhi
Deep Chauhan
Dedifferentiated liposarcoma (DDLPS) is a rare, aggressive subtype of liposarcoma characterized by the presence of both well-differentiated and high-grade sarcomatous components. We present a case of DDLPS diagnosed in a 23 years old male patient with an abdominal mass. This report highlights the clinical presentation, diagnostic workup, treatment, and outcomes of this case.
Keywords: Dedifferentiated, Liposarcoma, Well-differentiated.
References
- Fletcher CD, Bridge JA, Hogendoorn P, Mertens F. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. IARC Press; 2013.
- Doyle LA. Sarcoma classification: an update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone. Cancer. 2014;120(12):1763–74.
- Bill KLJ, Seligson ND, Hays JL, Awasthi A, Demoret B, Stets CW, et al. Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma. Oncologist. 2019;24(7):989–96.
- Crago AM, Dickson MA. Liposarcoma: Multimodality Management and Future Targeted Therapies. Surg Oncol Clin N Am. 2016;25(4):761–73.
- Fazel M, Dufresne A, Vanacker H, Waissi W, Blay JY, Brahmi M. Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond. Cancer. 2023;15(6):1643.
- Fletcher CD, Bridge JA, Hogendoorn P, Mertens F. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. IARC Press; 2013.
- Doyle LA. Sarcoma classification: an update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone. Cancer. 2014;120(12):1763–74.
- Ray-Coquard I, Blay JY, Italiano A, Cesne AL, Penel N, Zhi J, et al. Effect of the MDM2 antagonist RG7112 in patients with advanced well-differentiated or dedifferentiated liposarcoma: a multicentre, proof-of-concept, non-randomised, phase 1 study. Lancet Oncol. 2012;13(11):1133–40.